Clinical Trials Logo

Islet Cell Tumor clinical trials

View clinical trials related to Islet Cell Tumor.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT00466856 Terminated - Clinical trials for Head and Neck Cancer

Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors

Start date: December 2003
Phase: Phase 2
Study type: Interventional

RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. PURPOSE: This phase II trial is studying how well internal radiation therapy works in treating patients with liver metastases from neuroendocrine tumors.

NCT ID: NCT00227617 Terminated - Lung Cancer Clinical Trials

Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

Start date: June 8, 2005
Phase: Phase 2/Phase 3
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as fluorouracil, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of neuroendocrine tumors by blocking blood flow to the tumor. Giving combination chemotherapy together with bevacizumab may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects of giving combination chemotherapy together with bevacizumab and to see how well it works in treating patients with advanced neuroendocrine tumors.

NCT ID: NCT00002947 Terminated - Lung Cancer Clinical Trials

Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer

Start date: October 1996
Phase: Phase 1
Study type: Interventional

RATIONALE: Radiation therapy uses high-energy x-rays and other sources to damage tumor cells. Giving radiation therapy in different ways may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of indium In 111 pentetreotide in treating patients who have refractory cancer.